Epidermal growth factor receptor mutations detected in tumors from Chinese "never smokers" with lung adenocarcinoma

Chinese Medical Journal

Volumn 118, Issue 9, 2005, Pages 769-771

  Ren, Guo Ping ^a   Wang, Theresa Y ^b   Pan, Qiu Lu ^a   Pao, William ^b   Huai, Jing ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Epidermal growth factor receptor; Mutation; Never smoker; Non small cell lung cancer; Tyrosine kinase inhibitors

Indexed keywords

ARGININE; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; LEUCINE; MUCIN; PROTEIN TYROSINE KINASE;

ADULT; AGED; AMINO ACID SUBSTITUTION; ARTICLE; CANCER STAGING; CHINESE; CIGARETTE SMOKING; CLINICAL ARTICLE; CONTROLLED STUDY; DNA DETERMINATION; EXON; FEMALE; GENE DELETION; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG ADENOCARCINOMA; LUNG RESECTION; MALE; MUTATIONAL ANALYSIS; POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS;

ADENOCARCINOMA; ADULT; AGED; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 18744381043     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (9)

1. Yang L, Parkin DM, Li LD, et al. Estimation and projection of the national profile of cancer mortality in China: 1991-2005. Br J Cancer 2004;90:2157-2166.
2. Kris M, Natale RB, Herbst R, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer. JAMA 2003;290:2149-2158.
3. Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 2003;21:2237-2246.
4. Mu XL, Li LY, Zhang XT, et al. Evaluation of safety and efficacy of gefitinib ('iressa', zd1839) as monotherapy in a series of Chinese patients with advanced non-small-cell lung cancer: experience from a compassionate-use programme. BMC Cancer 2004; 4:51.
5. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-2139.
6. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-1500.
7. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from " never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 2004;101:13306-13311.
8. Parra HS, Cavina R, Latteri F, et al. Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib ('lressa', ZD1839) in non-small-cell lung cancer. Br J Cancer 2004;91:208-212.
9. Sirotnak F, Zakowski M, Miller V, et al. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by co-administration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin Can Res 2000;6:4885-4892.